Stifel Nicolaus Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI) had its price objective upped by Stifel Nicolaus from $34.00 to $41.00 in a research report released on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other analysts have also issued reports on DNLI. UBS Group began coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd. Wolfe Research initiated coverage on Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Wedbush lowered their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Finally, BTIG Research raised their price target on Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.82.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $19.74 on Thursday. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -6.65 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The firm’s 50 day simple moving average is $20.43 and its 200-day simple moving average is $17.81. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the firm posted ($0.67) earnings per share. Analysts expect that Denali Therapeutics will post -2.71 EPS for the current year.

Insiders Place Their Bets

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This trade represents a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics during the second quarter worth approximately $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics in the third quarter valued at about $29,000. State of Wyoming acquired a new position in Denali Therapeutics during the 2nd quarter worth approximately $29,000. Aster Capital Management DIFC Ltd acquired a new position in Denali Therapeutics during the fourth quarter worth $57,000. Finally, Quarry LP acquired a new position in shares of Denali Therapeutics during the 3rd quarter worth $64,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA accelerated approval of AVLAYAH (tividenofusp alfa‑eknm), Denali’s first commercial drug and the first transferrin‑receptor (brain‑penetrant) biologic for Hunter syndrome; approval includes a Rare Pediatric Disease PRV and Denali is launching U.S. commercialization and patient support services. GlobeNewswire: DNLI FDA Approval Zacks: Denali Wins FDA Nod
• Positive Sentiment: Multiple brokerages boosted price targets and ratings today (Morgan Stanley to $42/overweight; Goldman Sachs to $40/buy; Stifel to $41/buy; BTIG, HC Wainwright, Baird also raised targets), signaling strong analyst conviction about AVLAYAH’s commercial and platform upside. Benzinga: Analyst Coverage Roundup
• Neutral Sentiment: Management hosted/announced a conference call and webcast to discuss approval and launch plans; an investor webcast and Seeking Alpha transcript provide additional color on commercialization timing, pricing strategy and the COMPASS confirmatory trial. Seeking Alpha: AVLAYAH Launch Transcript
• Negative Sentiment: The FDA approval is accelerated and based on a biomarker (CSF heparan sulfate); continued approval may be contingent on confirmatory Phase 2/3 COMPASS trial results — this creates execution and regulatory risk that could weigh on the stock if confirmatory data are delayed or mixed. GlobeNewswire: Approval Details & Risks
• Negative Sentiment: Reports show recent insider sales and significant institutional portfolio moves (large reductions by some funds reported), which can create near‑term supply pressure and headline risk despite the approval. QuiverQuant: Insider & Institutional Activity

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.